CSF1R标记具有AML传播特性的胎儿造血多能祖细胞亚群
本研究在小鼠模型中证明,表达CSF1R的胎儿淋巴系始动多能祖细胞(LMPP)在诱导KMT2A::MLLT3后产生急性髓系白血病(AML),其髓系表型部分依赖CSF1R信号。公共数据集分析确认人类胚胎早期存在胎儿特异性CSF1R+ LMPP群体,且抑制CSF1R可导致KMT2A::MLLT3+儿童白血病细胞系显著死亡。
要点
- CSF1R+ LMPP是KMT2A::MLLT3+婴儿AML的候选起源细胞。
- CSF1R信号部分驱动白血病髓系表型,抑制可致细胞死亡。
- 人类胚胎早期存在胎儿限制性CSF1R+ LMPP群体。
核心结论
- KMT2A::MLLT3+婴儿AML可能起源于胎儿肝脏CSF1R+ LMPP。
- 抗CSF1R CAR-T细胞疗法可能使这类患者获益。
研究设计与样本
- 研究采用小鼠模型诱导KMT2A::MLLT3,并分析公共数据集及儿童白血病细胞系。
主要发现
- 小鼠中KMT2A::MLLT3诱导的CSF1R+ LMPP产生AML,髓系表型部分依赖CSF1R信号。
- KMT2A::MLLT3+ CSF1R+ LMPP具有干细胞样和髓系偏向表达特征,需自噬扩增并形成原始细胞样集落。
- 公共数据集确认人类胚胎早期存在胎儿限制性CSF1R+ LMPP群体。
- 抑制CSF1R导致KMT2A::MLLT3+儿童白血病细胞系显著细胞死亡。
临床怎么用
- CSF1R可作为KMT2A::MLLT3+婴儿AML的潜在治疗靶点。
- 抗CSF1R CAR-T细胞疗法值得在这类患者中探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KMT2A-rearranged infant leukaemia is one of the most severe malignancies in infants and children, and is characterised by a very aggressive phenotype and lineage plasticity. KMT2A::MLLT3 is among the most common translocations initiating leukaemia in infants, where it can manifest with a myeloid or lymphoid leukaemia phenotype. The cell-of-origin and the mechanisms driving lineage choice in KMT2A::MLLT3+ infant leukaemia are poorly understood. In this study, we show that a subset of foetal lymphoid-primed multipotent progenitors (LMPPs) expressing the Colony-Stimulating Factor 1 receptor (CSF1R) gives rise to acute myeloid leukaemia (AML) upon KMT2A::MLLT3 induction in a mouse model, with the myeloid phenotype, at least in part, being dependent on CSF1R signalling. In line with their leukaemia-propagating properties, KMT2A::MLLT3 + CSF1R+ LMPPs possess a stem cell-like and myeloid-biased expression signature and require autophagy to expand and form blast-like colonies in methylcellulose. Interrogation of public datasets confirms the existence of a human foetal-restricted CSF1R+ LMPP population at early stages of embryonic development. Finally, CSF1R inhibition on a KMT2A::MLLT3+ paediatric leukaemia cell line resulted in significant cell death, suggesting that CSF1R could be therapeutically targeted in these patients. Our findings suggest that KMT2A::MLLT3+ infant AML may originate from foetal liver CSF1R+ LMPPs, and that these patients may benefit from anti-CSF1R-CAR-T cell therapy.
引用
- Camiolo G, González Silvera D, Leah T, et al. CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties. Leukemia. 2026. PMID: 41545699. doi:10.1038/s41375-025-02856-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。